Synerkine Pharma B.V., an Utrecht, The Netherlands-based developer of fusion proteins for the treatment of chronic pain, closed a €3.3m Series A financing.
Backers included Thuja Capital, an undisclosed private investor, and the company’s founders.
The company intends to use the funds to build its pipeline of novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain.
Founded in 2018 by Hans Preusting, CEO, Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain.
The company has licensed the exclusive rights of its lead compound, a fusion protein of IL4 and IL10, from the University Medical Center Utrecht (UMCU), the Netherlands. This fusion protein targets common regulatory mechanisms in different types of chronic pain.
FinSMEs
25/03/2019